Log In
BCIQ
Print this Print this
 

Tuberculosis vaccine (Tuberculosis IC31) (H1IC)

  Manage Alerts
Collapse Summary General Information
Company Valneva SE
DescriptionRecombinant subunit vaccine containing TB antigens Ag85B and ESAT6 combined with an adjuvant, IC31
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationTuberculosis
Indication DetailsPrevent tuberculosis (TB) infection
Regulatory Designation
PartnerSanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$174.4M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/03/2013

$174.4M

0

Undisclosed

Get a free BioCentury trial today